Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group at the Department of Paediatrics, and Ashall Professor of Infection and Immunity has today been elected a Fellow of the Royal Society.

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group, has been elected a Fellow of the Royal Society

This accolade is one of the highest honours in science and is given to individuals who have made a "substantial contribution to the improvement of natural knowledge, including mathematics, engineering science and medical science". The award recognises his unique contributions to understanding human immunity, his ground-breaking research on vaccines to prevent life-threatening childhood diseases like typhoid, meningitis and pneumonia, and his invaluable leadership in the development of vaccines for outbreaks of influenza, Ebola, and COVID-19 among others.

Professor Sir Andrew Pollard said: "It is a huge honour to be elected as a Fellow of the Royal Society to join these most distinguished scientists of our time, standing on the shoulders of those past Fellows who changed our world over the past three and a half centuries.  I am more than aware that this is not about me but recognition of the large team of brilliant researchers at the Oxford Vaccine Group and our global collaborators who have made extraordinary contributions to improving lives through immunisation ."

The Royal Society, established over 360 years ago, is the world's oldest scientific academy in continuous existence, dedicated to promoting excellence in science.  

Similar stories

First Volunteer Receives Lassa Fever Vaccine in Cutting-edge Oxford Trial

The first volunteer has received a dose in a first-in-human trial of Oxford’s Lassa vaccine, marking a major milestone in the fight against the deadly virus. The trial, conducted by the Oxford Vaccine Group, and funded by the Coalition for Epidemic Preparedness Innovations (CEPI), will assess the safety and immune response of the ChAdOx1 Lassa vaccine. 31 people aged 18-55 will participate in the trial in total.